| 000 | 01713 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518082622.0 | ||
| 264 | 0 | _c20210128 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1098-6596 | ||
| 024 | 7 |
_a10.1128/AAC.02012-19 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDiacon, Andreas H | |
| 245 | 0 | 0 |
_aFourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _c03 2020 |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntitubercular Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEthambutol _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xtherapeutic use |
| 650 | 0 | 4 |
_aLinezolid _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 |
_aPyrazinamide _xtherapeutic use |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aSouth Africa |
| 650 | 0 | 4 |
_aSputum _xmicrobiology |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xdrug therapy |
| 700 | 1 | _aDe Jager, Veronique R | |
| 700 | 1 | _aDawson, Rodney | |
| 700 | 1 | _aNarunsky, Kim | |
| 700 | 1 | _aVanker, Naadira | |
| 700 | 1 | _aBurger, Divan A | |
| 700 | 1 | _aEveritt, Daniel | |
| 700 | 1 | _aPappas, Frances | |
| 700 | 1 | _aNedelman, Jerry | |
| 700 | 1 | _aMendel, Carl M | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 64 _gno. 4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.02012-19 _zAvailable from publisher's website |
| 999 |
_c30566634 _d30566634 |
||